Previous 10 | Next 10 |
Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for mu...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Phase 2 data evaluating the safety of suprachoroidal administration using its first ...
On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 On Track to Submit IND in Choroidal Metastasis in 2H 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugat...
Gainers: Curis ( CRIS ) +36% . Allarity Therapeutics ( ALLR ) +23% . Codiak BioSciences ( CDAK ) +21% . Cassava Sciences ( SAVA ) +17% . AlerisLife ( ALR ) +11% . Losers: Blue Water Vaccines ( BWV ) -27% ...
Aura Biosciences press release ( NASDAQ: AURA ): Q2 GAAP EPS of -$0.46 beats by $0.01 . As of June 30, 2022, Aura had cash and cash equivalents and marketable securities totaling $122.1 million. Aura believes its current cash and cash equivalents and marketable securit...
On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 Aura Bioscienc...
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, and Julie Feder, Chief Financi...
Aura Biosciences ( NASDAQ: AURA ) is trading higher in the morning hours Tuesday after JMP Securities issued an Outperform rating as it started coverage on the clinical-stage biotech citing its novel therapeutic platform. The virus-like drug conjugates (VDC) platform Aura ...
The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' ( NASDAQ: AURA ) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate...
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
News, Short Squeeze, Breakout and More Instantly...
Aura Biosciences Inc. Company Name:
AURA Stock Symbol:
NASDAQ Market:
Aura Biosciences Inc. Website:
(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall speaks with Proactive soon after announcing the company has raised A$10 million via a share placement at A$0.185 per share to advance development across the company’s project portfolio. The placement was supported by exis...
(NewsDirect) Aura Energy Limited (ASX: AEE, AIM: AURA) CEO Dave Woodall responds to a recent report that the Industry Committee of the Swedish parliament has voted to reject a number of private members’ motions supporting an immediate lifting of the ban on uranium mining in Sweden. He ...
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track ...